Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.25p +5.15% 25.50p 25.00p 26.00p 25.50p 24.00p 24.25p 433,432 16:24:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 52.19

Futura Medical Share Discussion Threads

Showing 16851 to 16872 of 16875 messages
Chat Pages: 675  674  673  672  671  670  669  668  667  666  665  664  Older
DateSubjectAuthorDiscuss
18/6/2019
17:01
Good old Grannypants always knows best.
j777j
17/6/2019
14:33
As my dear old gran used to tell me "all good things come to those that wait"
ragnarr
17/6/2019
13:27
Simply need US bio fund or two onboard and the shares will rerate.
j777j
17/6/2019
12:19
Liberum's figures are ultra conservative and that simply amplifies the value here.
j777j
17/6/2019
11:56
Thanks J777J.
rrr
17/6/2019
11:47
Liberum "The multi-billion dollar market for erectile dysfunction (ED) therapies continues to be dominated by PDE-5 inhibitors, despite a slow onset of action and negative side-effects. We believe Futura’s MED2005 addresses these issues and expect positive P3 data in December. Our confidence is driven by compelling P2 data, a non-binary set of potential outcomes, and a rock-solid safety profile. With a market cap of just £50m vs a peak sales potential of c.£500m, we think the market misses this low risk potential. BUY." "Key catalyst due by Dec 2019 Unlike with most drug discovery businesses, there is not long to wait for the key catalyst, with the headline P3 data due by December. This could drive >500% upside." Yes >500% upside!! "Liberum view: Headline data from FM57 is due by the end of December 2019, which is the key catalyst for the shares. This data alone should be enough to secure a significant outlicensing agreement, but more importantly de-risk the confirmatory second P3 study." "We have not provided much detail on potential competition in the pipeline, as frankly we do not see any at this stage."
j777j
17/6/2019
11:34
Just a game of patience here, happy holding.. chart looks good though! One on the move, outdoors be under valued too (C4XD) dyor as usual
ny boy
17/6/2019
09:49
>>>martinelwick You can download the note from Research tree https://www.research-tree.com/companies/uk/pharmaceuticals/futura-medical
timbo003
17/6/2019
08:46
Hi can you provide the link.
martinelwick
17/6/2019
08:18
Liberum 60p price target fair value and 137p high end
j777j
17/6/2019
08:10
Bullish research report from Liberum today."High probability of success,low valuation......"
j777j
12/6/2019
15:18
I always blame my partner !
mikethebike4
12/6/2019
08:51
Down to Liberum finding realInstitutional support.
wantage
12/6/2019
02:57
The repartition is vapid.
glavey
11/6/2019
11:16
Between 8 aug 2016 and 5 sep 2016,the share price went from 21p to 80p on positive news regarding the med gel. Can have quite some moves.
j777j
11/6/2019
10:57
Needs some decent new US investors onboard. The rating Fum gets here is minuscule to how it would be valued stateside,for a co with so much potential. Smaller caps in general are cheapest they have been for decades.
j777j
11/6/2019
08:34
The pond is shrinking these days, I know a few traders in NYC that are buying into U.K. equities as the exchange rate is so favorable, they have taken the view UK equities are trading at a big discount.
ny boy
11/6/2019
08:12
I note the author of the Guardian article is a regular contributor to the New York Times. It would be nice if the article makes it across the pond.
j777j
11/6/2019
07:17
They simply need to trumpet the investment case. Awaiting UK regulatory approval for the first pain gel product. Med2005 In commercial negotiations with licencees.. 15% royalties are forecast. Total upfront and milestone payments for EU and USA $90 million are forecast. Over $1billion peak sales are forecast. First major ED development in 20 years. 300 million men suffer ED and that is climbing rapidly as populations age and obesity and unhealthy living are on the rise too. Futura have a topical product that is fast acting.Completely bypassing any risks incurred by swallowing a pill like viagra.
j777j
11/6/2019
05:05
Maybe they should try ramping instead, that seems to have been more successful of late.
glavey
10/6/2019
18:27
Well hopefully like the rest of us they will learn.
j777j
10/6/2019
16:43
'management' is not Futura's forte !
mikethebike4
Chat Pages: 675  674  673  672  671  670  669  668  667  666  665  664  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190618 16:41:23